FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Status:
RECRUITING
Trial end date:
2027-06-02
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms